Physician Resources

NICE recommends rivaroxaban for acute coronary syndrome


 

References

Rivaroxaban has been recommended by the U.K. National Institute for Health and Care Excellence (NICE) as a treatment option for prevention of blood clots in adults who have had acute coronary syndrome with elevated cardiac biomarkers, the agency announced in a statement.

NICE officials recommended rivaroxaban (Xarelto), in combination with aspirin plus clopidogrel or aspirin alone, as an option for preventing atherothrombotic events in patients who have had a heart attack. Assessment of clinical-effectiveness evidence was based on data from an international, multicenter, randomized controlled trial. An independent appraisal committee considered clinical and cost-effectiveness evidence before making the recommendation.

Rivaroxaban, manufactured by Bayer and marketed by Janssen Pharmaceuticals, is an orally active direct factor Xa inhibitor.

Clinicians should regularly reassess the benefits and risks of continuing treatment with rivaroxaban, the agency recommended, and a decision on continuation of treatment should be made no later than 12 months after starting treatment.

Read the full guideline statement here.

mbock@frontlinemedcom.com

Recommended Reading

Familial hypercholesterolemia: Clues to catching it early
MDedge Family Medicine
FDA approves alirocumab, first injectable lipid-lowering biologic therapy
MDedge Family Medicine
Poor glycemic control upped chances of coronary events after CABG
MDedge Family Medicine
Adding ezetimibe to atorvastatin boosts coronary plaque regression
MDedge Family Medicine
Practice invites patients to run a 5K with their doctor
MDedge Family Medicine
Have we done enough to educate patients about e-cigarettes?
MDedge Family Medicine
LVEF improvements over time in ICD recipients tied to lower mortality
MDedge Family Medicine
Heart failure readmissions? Suspect senile amyloidosis
MDedge Family Medicine
Anticoagulant therapy not contraindicated in brain metastases
MDedge Family Medicine
Proglycem found to increase pulmonary hypertension risk in infants
MDedge Family Medicine